Cronos Group Inc CRON Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$3.61 down $0.11, 2.96% at close Nov 6
Last close · Previous close $3.72
- Market cap
- $1.35BAt the Nov 6 close
- Dividend yield
- NoneLast 12 months
Price chart
$3.61down $0.11, 2.96%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$3.72Nov 5
- Volume1.32MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.06MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.28 to $3.91; now $3.61
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CRON beat the S&P 500 in 6 of 7 periods.
| Period | CRON and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRON: up 9.9% S&P 500: down 5.6% | CRON beat the S&P 500 by 15.5 percentage points Beat |
| 3M | CRON: up 17.6% S&P 500: down 4.1% | CRON beat the S&P 500 by 21.7 percentage points Beat |
| YTD | CRON: up 37.3% S&P 500: up 8.7% | CRON beat the S&P 500 by 28.6 percentage points Beat |
| 1Y | CRON: up 46.2% S&P 500: up 10.9% | CRON beat the S&P 500 by 35.3 percentage points Beat |
| Long term | ||
| 3Y | CRON: up 90.0% S&P 500: up 75.0% +23.9% vs +20.5% a year | CRON beat the S&P 500 by 15.0 percentage points Beat |
| 5Y | CRON: down 32.4% S&P 500: up 67.8% −7.5% vs +10.9% a year | CRON trailed the S&P 500 by 100.2 percentage points Trailed |
| 10Y | CRON: up 366.4% S&P 500: up 313.1% +16.6% vs +15.2% a year | CRON beat the S&P 500 by 53.3 percentage points Beat |
$10,000 invested in CRON 10 years ago (Nov 4, 2016) would be worth about $46,641 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
CRON beat the S&P 500 in 6 of 7 periods.
| Period | CRON and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRON: up 9.9% S&P 500: down 5.6% | CRON beat the S&P 500 by 15.5 percentage points Beat |
| 3M | CRON: up 17.6% S&P 500: down 4.3% | CRON beat the S&P 500 by 21.9 percentage points Beat |
| YTD | CRON: up 37.3% S&P 500: up 7.8% | CRON beat the S&P 500 by 29.5 percentage points Beat |
| 1Y | CRON: up 46.2% S&P 500: up 9.7% | CRON beat the S&P 500 by 36.5 percentage points Beat |
| Long term | ||
| 3Y | CRON: up 90.0% S&P 500: up 68.8% +23.9% vs +19.1% a year | CRON beat the S&P 500 by 21.2 percentage points Beat |
| 5Y | CRON: down 32.4% S&P 500: up 56.9% −7.5% vs +9.4% a year | CRON trailed the S&P 500 by 89.3 percentage points Trailed |
| 10Y | CRON: up 366.4% S&P 500: up 252.6% +16.6% vs +13.4% a year | CRON beat the S&P 500 by 113.8 percentage points Beat |
$10,000 invested in CRON 10 years ago (Nov 4, 2016) would be worth about $46,641 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$23.70
Closing high on . Now 84.8% below that record.
Split-adjusted daily closes since Jul 12, 2016.
Stock splits
CRON hasn’t split since its price history begins in 2016.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
Not reported
Other valuation measures
- 7.5×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 1.3×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 16.0×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - 3.90%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $553.20MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CRON DCF in Excel. Value Cronos Group with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $179.09Mup 37.5%
- Net income
- $69.98Mup 278.5%
- Diluted EPS
- Not reported
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $34.26M | $8.35M | $0.02 |
| Q4 FY24 (Dec 31, 2024) | $30.30M | $43.73M | $0.12 |
| Q1 FY25 (Mar 31, 2025) | $32.26M | $6.12M | $0.02 |
| Q2 FY25 (Jun 30, 2025) | $33.46M | −$39.71M | −$0.10 |
| Q3 FY25 (Sep 30, 2025) | $36.34M | $25.96M | Not reported |
| Q4 FY25 (Dec 31, 2025) | $44.53M | −$1.82M | Not reported |
| Q1 FY26 (Mar 31, 2026) | $45.21M | $13.75M | $0.04 |
| Q2 FY26 (Jun 30, 2026) | $53.01M | $32.09M | $0.09 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $64.56M | −$396.11M | −$1.07 |
| FY22 (Dec 31, 2022) | $86.75M | −$168.73M | −$0.45 |
| FY23 (Dec 31, 2023) | $87.24M | −$73.96M | −$0.19 |
| FY24 (Dec 31, 2024) | $117.62M | $41.08M | $0.11 |
| FY25 (Dec 31, 2025) | $146.59M | −$9.45M | −$0.02 |
Margins
- Gross 45.9%
- Operating −1.4%
- Net 39.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $52.66MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$60.05MLast 12 months
- Capital spending$7.39MLast 12 months
- 29.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $38.99MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$38.99MLast 12 months
74% of free cash flow
Balance sheet
- $848.93MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$1.30MAs of Jun 30, 2026
- Net cash$847.63MAs of Jun 30, 2026
- 16.18As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 7 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 6.5%Last 12 months
Over the last 12 months, Cronos Group’s net income was 6.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 5.9%Last 12 months
Over the last 12 months, Cronos Group’s net income was 5.9% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Cronos Group Inc
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach ®, PEACE NATURALS ® and Lord Jones ®.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Ontario, Canada
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CRON news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CRON stock FAQ
What is CRON stock’s price today?
Cronos Group (CRON) traded at $3.61 at the close on , down $0.11 (2.96%) from the previous close of $3.72. Over the past 52 weeks it has traded between $2.28 and $3.91.
If you invested $1,000 in CRON 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CRON on would be worth about $4,664 at the close on , a total return of +366.4%. The same $1,000 would be worth $676 if invested five years ago and $1,462 if invested one year ago. Past performance doesn’t predict future returns.
What is Cronos Group’s market cap?
Cronos Group’s market capitalization is about $1.3 billion. That’s Tiingo’s daily market cap for , at that day’s closing price of $3.61 (how market cap works). Cronos Group reported 373.66M shares outstanding at the end of its latest quarter ().
How much revenue does Cronos Group make?
Cronos Group reported $179.1 million of revenue over the four quarters to , up 37.5% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $53.0 million, up 58.4% from a year earlier.
Is Cronos Group profitable?
Yes. Cronos Group earned $70.0 million of net income over the four quarters to , a net margin of 39.1%, and its operating margin was −1.4% (what margins tell you).
Does CRON pay a dividend?
Cronos Group hasn’t paid a dividend in the last twelve months.
What is CRON’s 52-week high and low?
Over the past 52 weeks CRON has traded as low as $2.28 and as high as $3.91. At $3.61 at the close on , it is 7.7% below that high and 58.3% above the low.
What is CRON’s all-time high?
CRON’s highest closing price was $23.70 on , adjusted for stock splits. At $3.61 at the close on , it is 84.8% below that record.
Has CRON stock ever split?
No. CRON hasn’t split since its price history begins in 2016.
How has CRON stock performed?
Including dividends and measured to the close on , CRON has returned +37.3% so far this year and +46.2% over the past year, and −32.4% over five years (−7.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Cronos Group in?
Cronos Group is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in Ontario, Canada.
What exchange does CRON trade on?
Cronos Group trades on the Nasdaq under the ticker symbol CRON. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.